Collegium Pharmaceutical, Inc. (COLL)
47.91
+0.48
(+1.01%)
USD |
NASDAQ |
Dec 05, 16:00
47.91
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.514B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 60.40% |
| Valuation | |
| PE Ratio | 29.82 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.396 |
| Price to Book Value | 5.511 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 3.407 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 51.32% |
Profile
| Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA. |
| URL | http://www.collegiumpharma.com |
| Investor Relations URL | https://ir.collegiumpharma.com |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 26, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA. |
| URL | http://www.collegiumpharma.com |
| Investor Relations URL | https://ir.collegiumpharma.com |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 26, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |